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Background
Non-cirrhotic portal hypertension has recently emerged as
a new entity in HIV-infected patients. Histological find-
ings often reveal different hepatic portal perivascular
abnormalities. In most cases it was related to previous
didanosine exposure. Although its recognition could be
more difficult, this drug-induced vascular damage in the
liver might also appear in HIV/HCV co-infected patients.
Clinical cases
Three HIV individuals with chronic hepatitis C presented
with complicated portal hypertension as oesophageal
variceal bleeding. Liver fibrosis measured by transient
elastometry did not reveal advanced liver fibrosis. Liver
function tests were completely normal. All subjects pre-
sented previous clinical signs of portal hypertension,
thrombopenia and splenomegaly, lasting on average 4
and 2 years, respectively. They had been exposed to dida-
nosine for long periods in the past. (Table 1.)
Discussion
Primary hepatic vascular damage induced by didanosine
might result in non-cirrhotic portal hypertension. This
condition may appear in HIV patients without any known
cause of liver disease, as well as superimposed to other
hepatic illnesses, as chronic hepatitis C. The recognition
of clinical classical signs of portal hypertension (e.g.
thrombopenia, splenomegaly) in the absence of a signifi-
cant liver fibrosis or synthetic function compromise may
alert to the possibility of this condition.
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Table 1: 
Case 1 Case 2 Case 3
Age (years) 41 49 42
Gender Male Female Male
Race Caucasian Caucasian Caucasian
Risk group IDU IDU IDU
On HAART Yes Yes Yes
Prior didanosine exposure (months) 64 30 44
CD4 count (cells/mm3) 351 168 324
Plasma HIV-RNA (copies/ml) <50 <50 <50
Platelet count/ul 78,000 57,000 81,000
Liver fibrosis stage (Metavir, stiffness KPa) F2 (9) F3 (11.5) F4 (15)
Splenomegaly Yes Yes Yes
